Fulgent Genetics, Inc. (FLGT) SEC Filings & Earnings Calls

Billing system transition delays impacting collection rate and revenue guidance.

“processing delays impacting our collection rate related to the final phase of the transition of our revenue cycle management and billing system” · word for word

Continued GAAP and non-GAAP losses indicate ongoing profitability challenges.

“GAAP loss of $29.5 million; Non-GAAP loss of $16.2 million”

Dependence on tax refund of $106.1M from IRS, which has been delayed.

“anticipated tax refund of approximately $106.1 million...have been delayed as a result of constrained resources at the IRS” · word for word

Customer concentration risk

“The decrease in precision diagnostics revenue was driven by the decline in revenue from our largest customer as this customer begins to perform tests internally.” · word for word

Billing system transition risk

“Our gross profit as a percentage of revenue, or gross margin, decreased from 42% in the three months ended June 30, 2025, to 30% in the three months ended June 30, 2026... driven by the lower collection rate and higher fixed costs, reducing operating leverage primarily resulting from processing and collections delays in connection with the final phase of the” · word for word

Intangible asset impairment risk

“During the three months ended June 30, 2026, we identified a triggering event with respect to a finite-lived customer relationship intangible asset acquired as part of the ANP acquisition, resulting from loss of a significant customer relationship. As a result, we recorded an impairment charge of $2.2 million.” · word for word

Insider Pledge Risk

“1,000,000 shares of Common Stock of the Trust are pledged as security pursuant to a pre-paid forward arrangement ... and 5,760,733 shares of Common Stock of the Trust are pledged as collateral for a credit facility provided to the Trust by The Charles Schwab Corporation.” · word for word

Insider Pledge Risk

“1,000,000 shares of Common Stock of the Trust are pledged as security pursuant to a pre-paid forward arrangement ... and 5,760,733 shares of Common Stock of the Trust are pledged as collateral for a credit facility provided to the Trust by The Charles Schwab Corporation.” · word for word

Potential dilution from new equity incentive plan.

“2026 Plan authorizes 2M new shares plus up to 1.5M from forfeited Prior Plan awards.”

Continued GAAP and non-GAAP losses; reliance on cash reserves

“GAAP loss of $24.8M; non-GAAP loss of $11.0M; adjusted EBITDA loss of $15.2M”

Customer Concentration Risk

“The decrease in precision diagnostics revenue was driven by the decline in revenue from our largest customer as this customer begins to perform tests internally.” · word for word

Margin Pressure from Acquisition Integration

“Because the acquired operations were included for only approximately two weeks of the quarter, we expect cost of revenue to increase in future quarters as the Bako Acquisition operations are more fully reflected in our consolidated results.” · word for word

Revenue Volatility from Project Timing

“The increase in BioPharma services revenue was primarily due to the timing of service projects, though this revenue is expected to remain variable due to the long sales cycle and fluctuations in project timing.” · word for word

Insider pledge risk

“1,000,000 shares of Common Stock of the Trust are pledged as security pursuant to a pre-paid forward arrangement... and 5,760,733 shares of Common Stock of the Trust are pledged as collateral for a credit facility provided to the Trust by The Charles Schwab Corporation.” · word for word

Clinical trial failure risk for FID-007 and FID-022

“We are investigating FID-007 in a Phase 2, randomized, multi-center, open-label trial ... we anticipate announcing our interim findings for this trial in June 2026, and we expect a full data readout by the second half of 2027.” · word for word

Related party transaction risk with ANP Technologies

“The Company incurred $0.6 million in expenses in the year ended December 31, 2025, prior to April 25, 2025, related to the licensing and development services and purchase of equipment from ANP.” · word for word

Insider pledge risk

“1,000,000 shares of Common Stock of the Trust are pledged as security pursuant to a pre-paid forward arrangement... and 5,760,733 shares of Common Stock of the Trust are pledged as collateral for a credit facility provided to the Trust by The Charles Schwab Corporation.” · word for word

Integration risk and potential goodwill impairment from acquisitions.

“Acquisitions closed with cash; post-closing adjustments and escrow arrangements indicate typical M&A risk.”

Customer concentration risk: largest customer moving significant volume in-house could pressure revenue in H1 2026.

“Our revenue guidance reflects the impact of our largest customer moving a significant volume of its work in-house.” · word for word

GAAP net loss persists despite non-GAAP profitability, indicating ongoing GAAP-level losses.

“GAAP loss of $23.4 million in Q4 2025; GAAP loss of $60.5 million for FY2025.”

Insider control risk

“Mr. Hsieh, our founder, Chief Executive Officer and Chairperson of our board of directors, beneficially owns approximately 28.3% of our outstanding voting equity as of December 31, 2025.” · word for word

Liquidity risk due to concentrated ownership

“As a result, fewer shares are actively traded in the public market, which reduces the liquidity of our common stock.” · word for word

License dependency risk for ADC program

“our ADC program is substantially dependent upon certain intellectual property rights for certain reagents.” · word for word

Integration risk from acquisition.

“Acquisition of multiple entities may pose integration challenges.”

Government shutdown could delay tax refunds impacting cash position.

“This number further assumes receipt of approximately $106 million in tax refunds prior to December 31, 2025, which may be delayed as a result of the current government shutdown.” · word for word

Customer Concentration

“one customer comprised $19.2 million, or 23%, of our revenue in the three months ended September 30, 2025.” · word for word

Reimbursement Risk

“Estimated collection amounts from insurance payors are subject to the complexities and ambiguities of billing, reimbursement regulations and claims processing.” · word for word

FDA Delays

“recently announced staff reductions at the FDA and the effects or residual effects of the current U.S. 'government shutdown,' which may affect the FDA’s ability to provide any required approvals or review in a timely manner.” · word for word